Experts discuss emerging MET-driven resistance data shaping second-line therapy for EGFR-mutated lung cancer

In a recent video segment, Dr. Jacob Sands sits down with Dr. Heather Wakelee to talk about the impact of new findings on MET-driven resistance in EGFR‑mutated non‑small cell lung cancer.

The conversation centers on how MET pathway activation can cause tumors to progress after first‑line EGFR‑targeted therapy, and what early clinical observations suggest about overcoming this resistance.

Both physicians explain that the emerging evidence is prompting clinicians to consider MET‑targeted agents or combination strategies when selecting second‑line treatments for patients whose disease has advanced despite initial EGFR inhibition.

The interview is part of a larger educational series that explores many facets of EGFR‑mutated NSCLC, from first‑line options to emerging antibody‑drug conjugates and value‑based assessments.